Kanada - Inggeris - Health Canada

dr reddy's laboratories ltd - pemetrexed (pemetrexed disodium) - powder for solution - 500mg - pemetrexed (pemetrexed disodium) 500mg - antineoplastic agents

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 120.82 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; hydrochloric acid - malignant pleural mesothelioma -pemetrexed-aft, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer - pemetrexed-aft in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed-aft as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604.12 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid; mannitol - malignant pleural mesothelioma -pemetrexed-aft, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer - pemetrexed-aft in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed-aft as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - pemetrexed disodium hemipentahydrate 120.82mg equivalent to 100 mg pemetrexed - powder for infusion - 100 mg - active: pemetrexed disodium hemipentahydrate 120.82mg equivalent to 100 mg pemetrexed excipient: hydrochloric acid mannitol sodium hydroxide - malignant pleural mesothelioma: pemetrexed-aft, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - pemetrexed disodium hemipentahydrate 604.12mg equivalent to 500 mg pemetrexed - powder for infusion - 500 mg - active: pemetrexed disodium hemipentahydrate 604.12mg equivalent to 500 mg pemetrexed excipient: hydrochloric acid mannitol sodium hydroxide - malignant pleural mesothelioma: pemetrexed-aft, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.

Kanada - Inggeris - Health Canada

accord healthcare inc - pemetrexed (pemetrexed disodium hemipentahydrate) - solution - 25mg - pemetrexed (pemetrexed disodium hemipentahydrate) 25mg - antineoplastic agents

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

emcure pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604.1 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid; nitrogen - malignant pleural mesothelioma pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

viatris limited - pemetrexed disodium hemipentahydrate 604.12mg equivalent to pemetrexed 500 mg - powder for infusion - 500 mg - active: pemetrexed disodium hemipentahydrate 604.12mg equivalent to pemetrexed 500 mg excipient: hydrochloric acid mannitol sodium hydroxide - malignant pleural mesothelioma pemetrexed infusion is indicated for the treatment of patients with malignant pleural mesothelioma in combination with cisplatin.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

eli lilly netherlands - pemetrexed - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.pemetrexed lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology.

Kesatuan Eropah - Inggeris - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - pemetrexed - carcinoma, non-small-cell lung; mesothelioma - folic acid analogues, antineoplastic agents - malignant pleural mesothelioma pemetrexed medac in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed medac in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed medac is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed medac is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,